Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. Dagogo-Jack I, Mitchell O, Codd E, Li A, et al. J Thorac Oncol 2025;20:1615-1625.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dagogo-Jack I, Mitchell O, Codd E, Li A, et al. Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol 2025;20:1615-1625.
PMID: 40578509